Emily

@emilykatehayes

Longtime medical journalist and editor. Also a pro jazz, blues and country vocalist. Tweets are my own. (Photos: Joseph O. Hayes)

San Francisco
Vrijeme pridruživanja: kolovoz 2009.

Tweetovi

Blokirali ste korisnika/cu @emilykatehayes

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @emilykatehayes

  1. Prikvačeni tweet
    18. tra 2019.

    The handle is up for my new edit role . Will be covering biomarkers, in vitro diagnostics, lab management and more. Our first meeting is . I will still be here tho. In fact, just perused LBAs. Can't take the pharma out of the girl I guess!

    Poništi
  2. 23. pro 2019.

    Planning for , first time at . Up for one year now! Please send testing related pitches of interest to lab professionals to me at Emily.hayes@bioinfoinc.com.

    Poništi
  3. 10. lis 2019.

    Discovering Healthcare Businesswomen’s Association with ⁦@monbonss⁩ at Angelica’s, Redwood City. Nice group of ladies!

    Poništi
  4. 21. ruj 2019.

    Great idea. Every meeting should have these!

    Poništi
  5. proslijedio/la je Tweet

    Riveting picture of face removed from its deceased donor about to be transplanted shortlisted for Photography Prize.

    Poništi
  6. 8. kol 2019.

    Well this is a first after going to medical meetings for 20 years. in Anaheim was evacuated. Guard said we could to come back in. But then, a shooter rumor, and we all panicked and ran! Ran all the way back to hotel. My new lab/pathology publication made debut there.

    Poništi
  7. 2. kol 2019.

    I am finding I want this as a hard copy, ordered.

    Prikaži ovu nit
    Poništi
  8. 2. kol 2019.

    I’ve been at my new job for four months next Tuesday! Editor of . Time flies. There is definitely some crossover of topics. I’m going to AACC meeting in Anaheim Sunday. Will any of you be there?

    Poništi
  9. proslijedio/la je Tweet
    1. kol 2019.

    News about the debut of , a hub for clinical professionals, at in Anaheim from our parent company .

    Poništi
  10. 27. srp 2019.

    If pembro and nivo are equal and nivo shows what happens wirh crossover better...does that mean firstline NSCLC better off with chemo, then pd-1?

    Prikaži ovu nit
    Poništi
  11. 26. srp 2019.

    I read the news about BMY partial failure and wanted more news on crossover. At ASCO 18 plenary they showed this affected Merck vs BMY monotherapy results. Do doctors still feel nivo vs pembro is Pepsi vs coke?

    Prikaži ovu nit
    Poništi
  12. 26. srp 2019.
    Prikaži ovu nit
    Poništi
  13. 11. srp 2019.
    Poništi
  14. 26. lip 2019.

    I said start with

    Prikaži ovu nit
    Poništi
  15. 26. lip 2019.

    A friend just asked me for info on renal cell carcinoma and I said I’d get back on it. Then I said, actually, did you know how many experts there are on Twitter? Worth signing up!

    Prikaži ovu nit
    Poništi
  16. 23. lip 2019.

    FDA approval of bremalanotide for low female sex desire hits us at our core. Do we as women believe that low sex desire is mostly psychological or physical? I lean toward psych but see no reason for drugs to not be cleared in physical basis unless on safety grounds.

    Prikaži ovu nit
    Poništi
  17. 21. lip 2019.

    Wow! FDA just approved $AMAG’s Vyleesi (bremalenototide) for low sexual desire in women. Second approved for this. This time no AdCom. I remember covering FDA sessions on how to boost number of sexual arousal and desire drugs for women years ago, was controversial.

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet
    20. lip 2019.

    We are hiring an experienced pharma reporter for and ideally based in Boston. I can't wait for some new blood to join our team.

    Poništi
  19. proslijedio/la je Tweet
    3. lip 2019.
    Odgovor korisniku/ci

    can't get ratings from heart disease.

    Poništi
  20. proslijedio/la je Tweet
    2. lip 2019.

    Intriguing but frustrating data on novel IO-IO combos. Still a ways to go to unravel this one. Dr. Goel sums it up.

    Poništi
  21. proslijedio/la je Tweet
    24. svi 2019.

    2 big drug approvals to kick off Memorial Day weekend. thinks this could be a blockbuster for HR+/HER- breast cancer in patients with PIK3CA mutations. Others failed including Novartis the first time around.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·